TY - JOUR
TI - Plasma biomarkers for the identification of women at risk for
early-onset preeclampsia
AU - Kolialexi, Aggeliki
AU - Tsangaris, George Th
AU - Sifakis, Stavros and
AU - Gourgiotis, Dimitris
AU - Katsafadou, Aggeliki
AU - Lykoudi, Alexandra and
AU - Marmarinos, Antonios
AU - Mavreli, Danai
AU - Pergialiotis, Vassilis and
AU - Fexi, Dimitra
AU - Mavrou, Ariadni
AU - Papaioanou, George K. and
AU - Papantoniou, Nikolas
JO - Expert Review of Proteomics
PY - 2017
VL - 14
TODO - 3
SP - 269-276
PB - TAYLOR & FRANCIS LTD LONDON
SN - 1478-9450, 1744-8387
TODO - 10.1080/14789450.2017.1291345
TODO - Preeclampsia; early onset preeclampsia; proteomics; 2-DE; mass
spectrometry; biomarkers
TODO - Background: To identify potential biomarkers in the 1st trimester of
pregnancy for the identification of women destined to develop early
onset preeclampsia (EOPE).Methods: Blood samples were obtained from
pregnant women at 11-13weeks of gestation. Women were followed up until
delivery. Five samples from EOPE complicated pregnancies and 5 from
unaffected ones were analysed using 2-DE and MALDI-TOF-TOF MS/MS. The
altered expression of selected proteins was verified by ELISA in an
extended sample cohort.Results: Twelve proteins were differentially
expressed in the plasma of women who subsequently developed EOPE as
compared to controls. Alpha-1-antitrypsin (A1AT), CD5 antigen-like
molecule (CD5L) Keratin, type I cytoskeletal 9 (K1C9), Myeloid cell
nuclear differentiation antigen (MNDA), Transferrin (TRFE) and Vitamin
D-binding protein (VTDB) were up-regulated with fold changes 3.14, 2.18,
1.53, 1.53, 4.26 3.38 respectively, whereas Alpha-2-HS-glycoprotein
(FETUA), Beta-2-glycoprotein 1 (APOH), Complement factor B (CFAB),
Haptoglobin (HPT), Vitronectin (VTNC) and Zinc-alpha-2-glycoprotein
(ZA2G) were down-regulated with fold changes -0.38, -0.76, -0.24, -0.47,
-0.23, and -0.50 respectively. The down-regulation of APOH, VTNC and HPT
was verified using ELISA.Conclusions: The differentially expressed
proteins represent potential biomarkers for the early screening for
EOPE. Follow-up experiments however are necessary for evaluation.
ER -